RAF1 and neoplasm: Sorafenib which is the first FDA approved drug for treatment of HCC, is a multi-kinase inhibitor that can block proliferation and angiogenesis of tumor cell by inhibiting a wide range of molecular targets including serine/threonine kinases, receptor tyrosine kinases, rapidly accelerated fibro sarcoma (Raf) kinases, vascular endothelial growth factor receptor 2, 3 (VEGFR2, VEGFR3), platelet-derived growth factor receptor (PDGFR), FLT3, Ret, and c-KIT [14, 15] (Fig. 1).